Isatuximab in Combination With Novel Agents

Phase 1-2 UMBRELLA Trial Evaluating Isatuximab With or Without Dexamethasone in Combination With Novel Agents Compared to Isatuximab With Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma (RRMM) - Master Protocol

More Information

Trial Status
Accepting patients
Trial Phase
Phase 1/2
Enrollment
258 patients (estimated)
Sponsors
Sanofi
Tags
Monoclonal Antibody, CD38, Randomization
Trial Type
Treatment
Last Update
1 week ago
SparkCures ID
1896
NCT Identifier
NCT04643002

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print a patient-friendly report to share with your patient.

We can help answer any questions and connect you (or your patient) with the study team.

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.